吉利德口服炎症性肠病药 emvistegrast 二期溃疡性结肠炎试验达主要终点，但属超大市值公司的增量式早期利好

Gilead Sciences ( GILD ) on Monday announced that its oral bowel disease therapy emvistegrast succeeded in a mid-stage trial for patients with ulcerative colitis, an inflammatory disease of the colon. Citing 12-week data, the company said that its Phase 2 SWIFT study for adults with moderate to severe ulcerative colitis reached the primary endpoint, as 66% of patients on 200 mg dosing of emvistegrast achieved a clinical response compared with 37% on placebo. Additionally, 31% of patients in the on-drug arm recorded clinical remission over the period compared with 8% in the off-drug arm. The once-daily pill was generally well tolerated, with adverse events and serious adverse events that were unrelated to the study drug, affecting only 36% and 2% of emvistegrast-treated recipients, respectively. However, 1% of participants dropped out due to AEs. The HIV drugmaker expects to begin a late-stage monotherapy trial for the  α4β7 integrin inhibitor in 2027. Quoting BMO Capital Markets, Reuters reported that the readout represented "an incremental positive for ​Gilead's inflammatory ​strategy that ⁠ establishes emvistegrast as a credible oral α 4 β 7 option.”